Clinical Study
Mean Platelet Volume in Hyperthyroid Toxic Adenoma Patients after Radioactive 131I Treatment
Table 2
The clinical and biochemical features of RAI treatment and controls.
| | | RAI treatment group | Control group |
| | 34 | 34 | | MPV (fL) | 8.53 ± 1.28 | 7.92 ± 0.91 | | Platelet count (×103/μL) | 265285 ± 68695 | 254411 ± 58584 | | Triglyceride (mg/dL) | 162.67 ± 109.17 | 98.05 ± 43.11 | | Total cholesterol (mg/dL) | 184.87 ± 35.82 | 199.87 ± 46.70 | | HDL-C (mg/dL) | 48.00 ± 11.50 | 58.17 ± 18.13 | | LDL-C (mg/dL) | 110.96 ± 39.73 | 132.16 ± 38.01 | | FT3 (pg/mL) | 4.54 ± 1.67 | 3.14 ± 0.79 | | FT4 (pg/mL) | 1.42 ± 0.66 | 1.53 ± 0.87 | | TSH (μIU/mL) | 0.27 ± 0.69 | 1.59 ± 1.05 | | CRP (mg/dL) | 2.69 ± 5.36 | 1.88 ± 1.39 |
|
|
HDL: high-density lipoprotein; LDL: low-density lipoprotein; TSH: thyroid stimulating hormone.
for RAI patients compared with controls.
|
